Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

elanco animal health gmbh alfred -

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

farmacevtska oblika nedoločena - hranila brez fenilalanina

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - donepezil - orodisperzibilna tableta - donepezil 4,56 mg / 1 tableta - donepezil

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - donepezil - orodisperzibilna tableta - donepezil 9,12 mg / 1 tableta - donepezil

Avrupa Birliği - Slovence - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinurija, paroksizmal - selektivni imunosupresivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Avrupa Birliği - Slovence - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromid - pljučna bolezen, kronična obstruktivna bolezen - adrenergics v kombinacijah z anticholinergics vklj. trojne kombinacije s kortikosteroidi - zdravilo xoterna breezhaler je indicirano za zdravljenje bronhodilatatorjev za vzdrževanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (kopb).

Avrupa Birliği - Slovence - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromid - pljučna bolezen, kronična obstruktivna bolezen - adrenergics v kombinacijah z anticholinergics vklj. trojne kombinacije s kortikosteroidi, zdravila za obstruktivne pljučne bolezni, - zdravilo ultibro breezhaler je indicirano za zdravljenje bronhodilatatorjev za vzdrževanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (kopb).

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

prašek - mlečni nadomestki

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

genepharm (europe) trading ltd. - rivastigmin - kapsula, trda - rivastigmin 4,5 mg / 1 kapsula - rivastigmin

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kapsula, trda - rivastigmin